Adam Zwolak, Ph.D. is a Director in the Biologics Discovery Department at J&J Innovative Medicine. His focus is on biologic therapeutic design fit-for-purpose. He was co-inventor of J&J’s T cell redirection, enhanced effector function, and ProAla bispecific antibody platforms, leading to more than 10 new clinical starts. Adam earned a Ph.D. in Structural Biology from New York University as an NIH-NHLBI graduate partnership fellow and completed postdoctoral training at the Perelman School of Medicine at the University of Pennsylvania. Adam has published 23 peer reviewed papers and is an inventor of over 20 granted or applied patents. Adam is an avid science fiction reader and enjoys running in his personal time.